Patients receiving brentuximab vedotin plus chemotherapy demonstrated a significant improvement in overall survival at 6 years compared with those on standard chemotherapy. Medscape Medical News
Log in met Medi-Access
Wilt u het gehele artikel lezen?
Log in met Medi-Access om verder te lezen
A New First-line Regimen for Advanced Hodgkin Lymphoma?
Medscape: Hematology/Oncology Headlines | Geplaatst op 11.06.2022 01:08